肿瘤学

澳门葡京赌博游戏正在引领一场变革癌症治疗的革命

首页 / 澳门葡京赌博游戏的治疗领域 /肿瘤学

澳门葡京赌博游戏有一个大胆的抱负，为各种形式的癌症提供治疗方法. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.

Our 肿瘤学 strategy is built with one goal in mind – to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. 澳门葡京赌博游戏广泛的下一代药物产品线, 以及澳门葡京赌博游戏对卓越执行力的关注, are aimed at expanding treatment options and improving outcomes for patients with solid tumours and haematological cancers. 

澳门葡京赌博游戏专注于四个战略重点：

  • Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, 抗体药物偶联物, 表观遗传学和细胞疗法
  • Advancing innovative clinical strategies to treat early stages of disease and relapsed or refractory patients
  • Building expertise and leadership in the most prevalent and highest mortality rate tumour types
  • 在全球范围内提供服务

展望未来

澳门葡京赌博游戏看到一个癌症不再是死亡原因的未来.

临床策略

澳门葡京赌博游戏的临床策略旨在改变生存.

药品：投资组合和管道

With our portfolio, our pipeline and our people, we aim to revolutionise cancer care.

病人的经验

We are catalysing changes in the practice of medicine to transform the patient experience.

澳门葡京赌博游戏的人民 & 文化

澳门葡京赌博游戏的员工、激情和创新是澳门葡京赌博游戏的动力.

澳门葡京赌博游戏的主要疾病领域

澳门葡京赌博游戏的重点是一些最具敌意和最难治疗的癌症. By understanding the complexities of cancer, we hope to achieve life-changing benefits for patients.

在聚光灯下

焦点：Lung Ambition Alliance

阅读更多关于肺野心联盟的信息

肺癌是澳门葡京网赌游戏研发的重点. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the 国际 Association for the Study of Lung Cancer (IASLC), 全球肺癌联盟（GLCC）, 和Guardant Health组成Lung Ambition联盟. Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, 提供创新药物，提高护理质量.

认识澳门葡京赌博游戏的团队

戴夫Fredrickson

肿瘤学事业部执行副总裁

查看Dave的个人资料
苏珊·加尔布雷斯

肿瘤学执行副总裁&D

查看Susan的个人资料
Ti华为How

国际肿瘤学副总裁

查看华为的个人资料

加入澳门葡京网赌游戏

帮助澳门葡京赌博游戏重新定义癌症治疗

Be among colleagues who are driven by our passion, our people and a culture of innovation. 澳门葡京赌博游戏重视勇气、好奇心、合作精神和学习热情. We encourage disruptive thinking where failure is an opportunity to learn – having the freedom to take risks without fear of failure.

澳门葡京网赌游戏的职业

澳门葡京赌博游戏的资源

共享临床试验信息

We publish information about the registration and results of all new and ongoing clinical trials for all products in all phases on our dedicated website.

关于澳门葡京赌博游戏药品的信息

澳门葡京赌博游戏的药品在个别国家获得了特定用途的批准. 访问您当地的澳门葡京网赌游戏网站以了解更多信息.

最新消息

Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer
  • 澳门葡京网赌游戏稿
Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
  • 澳门葡京网赌游戏稿
Enhertu granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
  • 澳门葡京网赌游戏稿
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
  • 澳门葡京网赌游戏稿
Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
  • 澳门葡京网赌游戏稿
Imfinzi perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
  • 澳门葡京网赌游戏稿
查看所有新闻和新闻稿